This post was originally published on this site The European Commission has approved two combination therapies based on Celgene‘s Revlimid (lenalidomide) and Imnovid (pomalidomide), added to Velcade (bortezomib) and dexamethasone, for the treatment of some adult patients with multiple myeloma. Revlimid, combined with Velcade and dexamethasone (RVd), is now indicated for the treatment of newly diagnosed, untreated adults…
Conditions
Conditions
Caregivers Can Help Preserve Alzheimer’s Patients’ Dignity
This post was originally published on this site Dignity diminished Alzheimer’s disease has a way of robbing a person’s dignity. Given enough time, it strips away what is basic to our loved one’s personality, including the very characteristics associated with dignity. It replaces their normal reserve, appearance, language, and seriousness of manner with odd behavior…
Investigational Alzheimer’s Therapy NNI-362 Receives FDA Approval to Enter Phase 1 Clinical Studies
This post was originally published on this site The U.S. Food and Drug Administration has approved Neuronascent’s investigational new drug (IND) application for NNI-362, its therapy candidate for Alzheimer’s disease, allowing it to move ahead with a Phase 1a clinical trial, the company announced. The first-in-human trial will evaluate the safety of NNI-362 in healthy…
Young Women More Likely to Face Aggressive BC Types, But Proper Treatment Improves Outcomes
This post was originally published on this site Young women are more likely than older ones to be diagnosed with more aggressive forms of breast cancer, but their outcomes can be good if they follow recommended treatments. That is the take-home messages of two studies presented at the recent ESMO Breast Cancer Congress 2019, held…
Therapy for Heavily Treated Multiple Myeloma Gets Fast Track Status from FDA
This post was originally published on this site Cellectar Biosciences’ candidate CLR 131 received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have failed at least four prior lines of therapy, the company announced. The designation is intended to speed the therapy’s development and…
Ampligen Showing Promise for Recurrent Ovarian Cancer in Phase 1/2 Trial, Phase 2 Study Now Recruiting
This post was originally published on this site Hemispherx Biopharma‘s experimental therapy Ampligen (rintatolimod) can change the tumor microenvironment to increase the amount of infiltrating T-cells, an approach that is showing promise in a Phase 1/2 clinical trial for recurrent ovarian cancer, according to the company. Funded in part by an Ovarian Cancer Specialized Program…
FDA Won’t Ban Sales of Breast Implants Linked to Lymphoma, But Considers Black Box Warning
This post was originally published on this site In announcing that breast implants linked to anaplastic large-cell lymphoma (ALCL) can continue to be sold in the United States, the U.S. Food and Drug Administration (FDA) proposed assurances that the potential risks of such implants are better known. In its recent statement, the agency said it would…
PRI-002, Oral Therapy Candidate for Alzheimer’s, Deemed Safe in Phase 1 Trial
This post was originally published on this site Alzheimer’s oral therapy candidate PRI-002, being developed by Priavoid, has proven safe for human use in healthy volunteers during a Phase 1 clinical trial. These positive trial results provide important evidence that supports progressing PRI-002 into studies of patients who have Alzheimer’s disease. “Our next goal is the…
Treatment Intensity Should Be Personalized in Women with HER2-positive Breast Cancer, Study Says
This post was originally published on this site Personalized treatment intensity is crucial to the success of less toxic and demanding therapies for women with HER2-positive breast cancer, according to a spokesperson from the European Society for Medical Oncology (ESMO). The remarks by Carmen Criscitiello, MD, PhD, accompanied updated results from the PERNETTA trial (EudraCT…
Japanese Researchers Use Hyperion Imaging Tool to Advance Treatment Discovery for Colorectal Cancer
This post was originally published on this site The National Cancer Center (NCC) in Japan is advancing its research into novel immunotherapies for colorectal cancer by using the Hyperion Imaging System, a powerful tool that enables simultaneous visualization of dozens of markers in a sample of tissue. The system, by Fluidigm, combines CyTOF technology with…
Revlimid Becomes Option for First-line Multiple Myeloma Treatment in England
This post was originally published on this site The National Institute for Health and Care Excellence (NICE) in England has recommended treatment with Revlimid (lenalidomide) and dexamethasone for multiple myeloma patients not eligible for a stem cell transplant or thalidomide therapy. “This decision is fantastic news for the myeloma patients who will be able to access…
Mirvetuximab Combos for Platinum-resistant Ovarian Cancer Showing Promise in Trial Updates
This post was originally published on this site Combining Immunogen‘s mirvetuximab soravtansine, an investigational antibody-drug conjugate, with Avastin (bevacizumab) showed signs of favorable efficacy and demonstrated a manageable safety profile in patients with platinum-resistant ovarian cancer, according to data from a Phase 1/2 clinical trial. In addition, initial data from a Phase 1 trial also…